Mechanism of Jianpi Liqi Decoction in treatment of functional dyspepsia by inhibiting mast cell activation and improving the expression of tight junction proteins
|更新时间:2022-08-03
|
Mechanism of Jianpi Liqi Decoction in treatment of functional dyspepsia by inhibiting mast cell activation and improving the expression of tight junction proteins
Shanghai Journal of Traditional Chinese MedicineVol. 55, Issue 11, Pages: 91-96(2021)
Xiongfei CHANG, Lingyu SHEN, Lihong ZHANG, et al. Mechanism of Jianpi Liqi Decoction in treatment of functional dyspepsia by inhibiting mast cell activation and improving the expression of tight junction proteins. [J]. Shanghai Journal of Traditional Chinese Medicine 55(11):91-96(2021)
DOI:
Xiongfei CHANG, Lingyu SHEN, Lihong ZHANG, et al. Mechanism of Jianpi Liqi Decoction in treatment of functional dyspepsia by inhibiting mast cell activation and improving the expression of tight junction proteins. [J]. Shanghai Journal of Traditional Chinese Medicine 55(11):91-96(2021) DOI: 10.16305/j.1007-1334.2021.2105034.
Mechanism of Jianpi Liqi Decoction in treatment of functional dyspepsia by inhibiting mast cell activation and improving the expression of tight junction proteins
Objective,2,To explore the mechanism of Jianpi Liqi Decoction in the treatment of functional dyspepsia (FD) by inhibiting degranulation of duodenal mast cells (MC), improving the expression of duodenal tight junction proteins (TJs) and restoring intestinal barrier function., Methods,2,Twenty-four 6-week-old SPF male SD rats were randomly divided into control group, model group, traditional Chinese medicine treatment group and CRH antagonist group, 6 rats in each grpup. Except for the control group, the FD model was established by tail clamping stress in other groups. After the establishment of the model, the control group and the model group were given pure water gavage, the traditional Chinese medicine treatment group given Jianpi Liqi Decoction gavage and the CRH antagonist group injected with antagonist intraperitoneally. After the intervention, the duodenum was taken and the expressions of corticotropin releasing hormone (CRH) major receptor 1 (CRHR1), MC marker protein trypsin (Tryptase), protease activated receptor 2 (PAR-2), myosin light chain kinase (MLCK), and TJs (JAM-A, ZO-1, claudin-1) in the duodenum were determined by Western blot.,Results,2,Compared with the control group, the expressions of CRHR1, Tryptase, PAR-2, MLCK in the duodenum of the model group were significant increased (,P,<,0.05), while the expressions of TJs (JAM-A, ZO-1, claudin-1) were down-regulated (,P,<,0.05). Compared with the model group, the expressions of CRHR1, Tryptase, PAR-2 and MLCK in the traditional Chinese medicine group and CRH antagonist group were down-regulated, while the expression of TJs (JAM-A, ZO-1, claudin-1) was significantly increased.,Conclusion,2,CRH-mediated activation of MC, release of inflammatory mediators and down-regulation of local TJs expression in the duodenum resulting in barrier damage may be one of the pathogenesis of FD, and Jianpi Liqi Decoction may inhibit the injury pathway, restore the function of local duodenal barrier and play a therapeutic role in FD.
关键词
功能性消化不良健脾理气方十二指肠促肾上腺皮质激素释放激素肥大细胞紧密连接蛋白肠道屏障中药研究
Keywords
functional dyspepsiaJianpi Liqi DecoctionduodenumCRHmast cellstight junction proteinsintestinal barriertraditional Chinese herbal medicine research
references
MAHADEVA S, FORD A C. Clinical and epidemiological differences in functional dyspepsia between the East and the West[J]. Neurogastroenterol Motil, 2016, 28(2): 167-174.
MIWA H, OSHIMA T, TOMITA T, et al. Recent understanding of the pathophysiology of functional dyspepsia: role of the duodenum as the pathogenic center[J]. J Gastroenterol, 2019, 54(4): 305-311.
JUNG H K, TALLEY N J. Role of the duodenum in the pathogenesis of functional dyspepsia: a paradigm shift[J]. J Neurogastroenterol Motil, 2018, 24(3): 345-354.
KOMORI K, IHARA E, MINODA Y, et al. The altered mucosal barrier function in the duodenum plays a role in the pathogenesis of functional dyspepsia[J]. Dig Dis Sci, 2019, 64(11): 3228-3239.
VANHEEL H, VICARIO M, VANUYTSEL T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia[J]. Gut, 2014, 63(2): 262-271.
TAKI M, OSHIMA T, LI M, et al. Duodenal low-grade inflammation and expression of tight junction proteins in functional dyspepsia[J]. Neurogastroenterol Motil, 2019, 31(10): e13576.
BEECKMANS D, RIETHORST D, AUGUSTIJNS P, et al. Altered duodenal bile salt concentration and receptor expression in functional dyspepsia[J]. United European Gastroenterol J, 2018, 6(9): 1347-1355.
TAKASHIMA S, TANAKA F, KAWAGUCHI Y, et al. Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice[J]. Neurogastroenterol Motil, 2020, 32(7): e13841.
ZHANG S S, ZHAO L Q, WANG H B, et al. Efficacy of modified LiuJunZi decoction on functional dyspepsia of spleen-deficiency and qi-stagnation syndrome: a randomized controlled trial[J]. BMC Complement Altern Med, 2013(13): 54.
WAUTERS L, TALLEY N J, MALKER M M, et al. Novel concepts in the pathophysiology and treatment of functional dyspepsia[J]. Gut, 2020, 69(3): 591-600.
PARADIS T, BÈGUE H, BASMACIYAN L, et al. Tight junctions as a key for pathogens invasion in intestinal epithelial cells[J]. Int J Mol Sci, 2021, 22(5): 2506.
NASCIMENTO J C, MATHEUS V A, OLIVEIRA R B, et al. High-fat diet induces disruption of the tight junction-mediated paracellular barrier in the proximal small intestine before the onset of type 2 diabetes and endotoxemia[J/OL]. Dig Dis Sci, 2020[2021-05-10]. https://pubmed.ncbi.nlm.nih.gov/33104937/https://pubmed.ncbi.nlm.nih.gov/33104937/.
VAN ITALLIE C M, ANDERSON J M. Architecture of tight junctions and principles of molecular composition[J]. Semin Cell Dev Biol, 2014(36): 157-165.
XU W, LU J, CHEN Y, et al. Impairment of CRH in the intestinal mucosal epithelial barrier of pregnant Bama miniature pig induced by restraint stress[J]. Endocr J, 2021, 68(4): 485-502.
SAGAMI Y, SHIMADA Y, TAYAMA J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome[J]. Gut, 2004, 53(7): 958-964.
ZHU H L, PI D A, LENG W B, et al. Asparagine preserves intestinal barrier function from LPS-induced injury and regulates CRF/CRFR signaling pathway[J]. Innate Immun, 2017, 23(6): 546-556.
VANUYTSEL T, MANROOY S V, VANHEEL H, et al. Psychological stress and corticotropin releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism[J]. Gut, 2014, 63(8): 1293-1299.
ZHONG C J, WANG K, ZHANG L, et al. Mast cell activation is involved in stress-induced epithelial barrier dysfunction in the esophagus[J]. J Dig Dis, 2015, 16(4): 186-196.
HAGIWARA S I, KAUSHAL E, PARUTHIYIL S, et al. Gastric corticotropin-releasing factor influences mast cell infiltration in a rat model of functional dyspepsia[J]. PLoS One, 2018, 13(9): e0203704.
LABUS J S, HUBBARD C S, BUELLER J, et al. Impaired emotional learning and involvement of the corticotropin-releasing factor signaling system in patients with irritable bowel syndrome[J]. Gastroenterology, 2013, 145(6): 1253-1261.
BUENO L, FIORAMONTI J. Protease-activated receptor 2 and gut permeability: a review[J]. Neurogastroenterol Motil, 2008, 20(6): 580-587.